Genedrive Plc logo

Genedrive Plc(LSE) GDR

Market Cap£19.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-99%
5 Year-94%
1 Year+440%
1 Month-14%
£0.01
+1.74%
+0.00Today
Genedrive Plc last closing stock price
MetricPriceDate
Last closeGBX 1.202026-10-01
Genedrive Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.69%GBX 1.182026-09-24
1 month-14.29%GBX 1.402026-09-01
3 month-7.69%GBX 1.302026-07-03
Year to date+38.74%GBX 0.862025-12-31
1 year+439.57%GBX 0.222025-10-01
3 year-85.2%GBX 8.112023-10-02
5 year-93.87%GBX 19.572021-10-01
Since inception-99.14%GBX 1.402007-04-10

Genedrive Plc Financials at a Glance

Market Cap

£19.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£1.68M

Net Income (TTM)

-£12.71M

EPS (TTM)

-£0.01

P/E Ratio

-1.54

Dividend

£0.00

Beta (Volatility)

0.12 (Low)

Price

£0.01

Volume

2,824,612

Open

£0.01

Previous Close

£0.01

Daily Range

£0.01 - £0.01

52-Week Range

£0.00 - £0.02

Estimated Earnings Date

Nov 24, 2026

GDR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genedrive Plc

Genedrive Plc is a molecular diagnostics company based in Manchester, UK, specializing in innovative point-of-care diagnostic platforms. Established in 2000, the company focuses on applications such as infectious disease identification, genetic profiling, and pathogen detection.

Products and Services
  • Genedrive HCV ID Kit for Hepatitis C virus detection
  • Genedrive BioPlex for military biothreat pathogen identification
  • Genedrive MT-RNR1-ID Kit for rapid neonatal genetic testing
Growth Outlook
  • Recent partnerships aim to enhance laboratory PCR testing automation
  • Expansion into international markets increases potential customer base
  • Focus on innovative diagnostics aligns with growing healthcare demands
Financial Highlights
  • Q2 2025 revenue of £463,000, showing a 66% increase from Q4 2024
  • Gross profit margin improved to 95% in Q2 2025
  • Cash reserves decreased to £387,000, indicating liquidity challenges
Genedrive Plc operates in the medical diagnostics and research sector, leveraging proprietary technology to deliver rapid and accurate diagnostic solutions. The company's flagship Genedrive system utilizes advanced PCR technology, allowing for quick amplification and detection of nucleic acids from various biological samples. This capability is crucial in addressing urgent healthcare needs, particularly in infectious disease management. The growth outlook for Genedrive is promising, driven by strategic partnerships and a commitment to innovation. The recent increase in revenue and improvement in gross profit margin reflect the company's potential to capitalize on the expanding market for point-of-care diagnostics. However, the decrease in cash reserves highlights the need for careful financial management as the company navigates its growth trajectory. Investors may find Genedrive Plc an intriguing opportunity within the healthcare sector, particularly given its focus on innovative diagnostic solutions and the potential for market expansion. The company's ability to adapt to changing healthcare demands will be critical in determining its future success.
AI Generated • Sep 4, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

CEO

Gino Miele, PhD

Website

www.genedriveplc.com

Headquarters

Manchester, GM M13 9XX, GB

GDR Financials

Key Financial Metrics (TTM)

Gross Margin

84.16%

Operating Margin

-518.84%

Net Income Margin

-500.75%

Return on Equity

-1044.57%

Return on Capital

-374.13%

Return on Assets

-304.62%

Earnings Yield

-64.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£19.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.61B

Volume

2.82M

Avg. Volume

4.36M

Financials (TTM)

Gross Profit

£1.34M

Operating Income

-£11.06M

EBITDA

-£13.29M

Operating Cash Flow

-£8.27M

Capital Expenditure

-£48.00K

Free Cash Flow

-£8.32M

Cash & ST Invst.

£387.00K

Total Debt

£500.00K

Genedrive Plc Performance Analysis

Genedrive Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30GBP 49,000N/A
20232023-06-30GBP 55,00012.2%
20242024-06-30GBP 332,000503.6%
20252025-06-30GBP 764,000130.1%
Genedrive Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3010.5%
Q22024-12-3133.1%
Q42025-06-3072.6%
Q22025-12-31-23.3%
Genedrive Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30GBP -0.04N/A
20232023-06-30GBP -0.04-0.9%
20242024-06-30GBP -0.056.9%
20252025-06-30GBP -0.01-80.1%
Genedrive Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-72.6%
Q22024-12-3154.6%
Q42025-06-3035.0%
Q22025-12-3163.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

£463.00K

+94.5%

Gross Profit

£441.00K

+267.5%

Gross Margin

95.25%

N/A

Market Cap

£19.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£448.07K

N/A

Employees

43

N/A

Net Income

-£2.44M

-19.7%

EBITDA

-£2.70M

-19.5%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

£387.00K

-68.4%

Total Debt

£500.00K

+287.6%

Accounts Receivable

£917.00K

-34.3%

Inventory

£341.00K

-36.7%

Long Term Debt

£500.00K

N/A

Short Term Debt

£0.00

-100.0%

Return on Assets

-3.05%

N/A

Return on Invested Capital

-65.13%

N/A

Free Cash Flow

-£1.85M

+23.6%

Operating Cash Flow

-£1.84M

+23.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PRM.LProteome Sciences plc
£0.01-0.34%
N4P.LN4 Pharma Plc
£0.00+0.00%
SUN.LSurgical Innovations Group plc
£0.00+0.00%
CNSL.LCambridge Nutritional Sciences plc
£0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$13.29+4.98%
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$76.90+0.04%
NKENike
$35.15-0.71%
INTCIntel
$120.00-0.19%

Questions About GDR

What is the current price of Genedrive Plc?

Genedrive Plc is trading at £0.01 per share.

What is the 52-week range for Genedrive Plc?

Over the past 52 weeks, Genedrive Plc has traded between £0.00 and £0.02.

How much debt does Genedrive Plc have?

As of the most recent reporting period, Genedrive Plc reported total debt of £0.00.

How much cash does Genedrive Plc have on hand?

Genedrive Plc reported £1.18M in cash and cash equivalents in its most recent financial results.

What is Genedrive Plc’s dividend yield?

Genedrive Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services